Jensa Morris: Why Low Molecular Weight Heparins Should Be the First Choice for VTE
Jensa Morris, Director of Smilow Hospitalist Service at Yale New Haven Hospital, shared a post on LinkedIn about a recent article by Youssef Saklawi et al, published in Journal of Hospital Medicine, adding:
“There are so many clinical interventions that we do reflexively despite a mountain of clinical evidence to the contrary.
Thank you Journal of Hospital Medicine and TWDFNR for reminding us that LMWH and not UFH should be first choice for patients requiring non-oral treatment for VTE, even for those who may later require thrombolysis or thrombectomy.”
Title: Things we do for no reason™: Routine use of unfractionated heparin for initial anticoagulation in venous thromboembolism
Authors: Youssef Saklawi, Mohamad Ali Tfaily, Bhargav Marthambadi, Adrian Umpierrez
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience